VMV. Alexandra Moser

V. Alexandra Moser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


V. Alexandra Moser has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The arsenic-Alzheimer's disease link: Emerging evidence and unanswered questions

    by Luz Jovita Dimas-Harms, V. Alexandra Moser

    Arsenic is a toxic heavy metal that reaches humans primarily through contaminated groundwater, presenting a persistent global public health concern. Chronic exposure, even at concentrations lower than current safety standards, disturbs brain development and function, raising concern that arsenic may contribute to Alzheimer's disease (AD). Wei et al. investigate early-life arsenic exposure and AD using Swedish national registries and geographic variation in groundwater arsenic. This work represents a critical step toward understanding whether historical environmental exposures in northern Europe have increased late-life neurodegenerative risk and underscores the importance of treating arsenic as a potentially modifiable environmental risk factor for AD.


  • Open Access

    Human iPSC‐Derived Mononuclear Phagocytes Improve Cognition and Neural Health across Multiple Mouse Models of Aging and Alzheimer's Disease

    by V. Alexandra Moser, Luz Jovita Dimas‐Harms, Rachel M. Lipman, Jake Inzalaco, Shaughn Bell, Michelle Alcantara, Erikha Valenzuela, George Lawless, Simion Kreimer, Sarah J. Parker, et al.

    Young blood or plasma improves cognitive function in aged animals but has limited availability. The current study generates a subtype of young blood cells from easily expandable induced pluripotent stem cells and evaluates their effects on age‐ and Alzheimer's disease (AD)‐associated cognitive and neural decline. In aging mice, intravenous delivery of induced mononuclear phagocytes (iMPs) improves performance in hippocampus‐dependent cognitive tasks, increases neural health, and reduces neuroinflammation. Hippocampal single nucleus RNA‐sequencing shows that iMPs improve the health of a subpopulation of mossy cells that are critically involved in the type of cognitive task in which iMPs improve performance, and shows that iMPs decrease the transcriptional age of several hippocampal cell types. Plasma proteomic analyses reveal that iMPs can also reverse age‐associated increases in serum amyloid levels. This is verified in vitro, where iMP‐conditioned media is shown to protect human microglia against cell death induced by serum amyloids. Finally, iMPs improve cognition in both young and aging 5×FAD mice, highlighting their potential as a prevention as well as an intervention strategy. Together, these findings suggest that iMPs provide a novel therapeutic strategy to target both age‐ and AD‐related cognitive decline.


  • The gap between amyloid pathology and cognition

    by V Alexandra Moser

    Nrf2 is a transcription factor critical for protecting the brain against oxidative stress and is decreased in Alzheimer's disease (AD) patients, making it a potential therapeutic target. The Curran lab previously identified a novel regulator, WDR23. Now, in a new study by Liu et al., they demonstrate that knocking out WDR23 in the 3xTg-AD mouse improves spatial working memory, interestingly, while increasing a measure of AD-like pathology. Their work brings up several interesting new questions and adds to a growing body of literature that highlights how the relationship between cognition and amyloid pathology is not as clearcut as once thought.

  • Open Access

    Microglial transcription profiles in mouse and human are driven by APOE4 and sex

    by V. Alexandra Moser, Michael J. Workman, Samantha J. Hurwitz, Rachel M. Lipman, Christian J. Pike, Clive N. Svendsen


  • Open Access

    Obesity Accelerates Alzheimer-Related Pathology inAPOE4but notAPOE3Mice

    by V. Alexandra Moser, Christian J. Pike

    Alzheimer’s disease (AD) risk is modified by both genetic and environmental risk factors, which are believed to interact to cooperatively modify pathogenesis. Although numerous genetic and environmental risk factors for AD have been identified, relatively little is known about potential gene-environment interactions in regulating disease risk. The strongest genetic risk factor for late-onset AD is the ε4 allele of apolipoprotein E (APOE4). An important modifiable risk factor for AD is obesity, which has been shown to increase AD risk in humans and accelerate development of AD-related pathology in rodent models. Potential interactions betweenAPOE4 and obesity are suggested by the literature but have not been thoroughly investigated. In the current study, we evaluated this relationship by studying the effects of diet-induced obesity (DIO) in the EFAD mouse model, which combines familial AD transgenes with humanAPOE3 orAPOE4. Male E3FAD and E4FAD mice were maintained for 12 weeks on either a control diet or a Western diet high in saturated fat and sugars. We observed that metabolic outcomes of DIO were similar in E3FAD and E4FAD mice. Importantly, our data showed a significant interaction between diet andAPOEgenotype on AD-related outcomes in which Western diet was associated with robust increases in amyloid deposits, β-amyloid burden, and glial activation in E4FAD but not in E3FAD mice. These findings demonstrate an important gene-environment interaction in an AD mouse model that suggests that AD risk associated with obesity is strongly influenced byAPOEgenotype.


  • Open Access

    Selective Androgen Receptor Modulator RAD140 Is Neuroprotective in Cultured Neurons and Kainate-Lesioned Male Rats

    by Anusha Jayaraman, Amy Christensen, V. Alexandra Moser, Rebekah S. Vest, Chris P. Miller, Gary Hattersley, Christian J. Pike

    The decline in testosterone levels in men during normal aging increases risks of dysfunction and disease in androgen-responsive tissues, including brain. The use of testosterone therapy has the potential to increase the risks for developing prostate cancer and or accelerating its progression. To overcome this limitation, novel compounds termed “selective androgen receptor modulators” (SARMs) have been developed that lack significant androgen action in prostate but exert agonist effects in select androgen-responsive tissues. The efficacy of SARMs in brain is largely unknown. In this study, we investigate the SARM RAD140 in cultured rat neurons and male rat brain for its ability to provide neuroprotection, an important neural action of endogenous androgens that is relevant to neural health and resilience to neurodegenerative diseases. In cultured hippocampal neurons, RAD140 was as effective as testosterone in reducing cell death induced by apoptotic insults. Mechanistically, RAD140 neuroprotection was dependent upon MAPK signaling, as evidenced by elevation of ERK phosphorylation and inhibition of protection by the MAPK kinase inhibitor U0126. Importantly, RAD140 was also neuroprotective in vivo using the rat kainate lesion model. In experiments with gonadectomized, adult male rats, RAD140 was shown to exhibit peripheral tissue-specific androgen action that largely spared prostate, neural efficacy as demonstrated by activation of androgenic gene regulation effects, and neuroprotection of hippocampal neurons against cell death caused by systemic administration of the excitotoxin kainate. These novel findings demonstrate initial preclinical efficacy of a SARM in neuroprotective actions relevant to Alzheimer's disease and related neurodegenerative diseases.